Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fel-O-Vax 3
- Development stage
- Unknown
- Lead developer
- Fort Dodge Laboratories
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
Fel-O-Vax 3 is an inactivated (killed virus) vaccine designed to protect healthy cats and kittens (8 weeks of age or older) against three significant feline infectious diseases: Feline Viral Rhinotracheitis, Feline Caliciviral Disease, and Feline Panleukopenia. The vaccine contains inactivated viral antigens from Feline Herpesvirus-1 (FHV-1), Feline Calicivirus (FCV), and Feline Panleukopenia Virus (FPV). By presenting these killed antigens, the vaccine stimulates an active immune response, aiding in the reduction of clinical signs and severity of disease upon exposure. Originally developed by Fort Dodge Animal Health, the product line was acquired by Boehringer Ingelheim and subsequently transitioned to Elanco Animal Health as part of a divestiture of companion animal vaccines. It is typically administered via subcutaneous or intramuscular injection in a two-dose primary series, followed by annual revaccination.
- Brand names
- Fel-O-Vax 3Fel-O-Vax3Fel-O-Vax-3
- Other names
- Fel-O-Vax IIIFeline Rhinotracheitis-Calici-Panleukopenia Vaccine
02
Targets
FPV (Feline panleukopenia virus)
Beyond the preview
Go deeper on Fel-O-Vax 3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fel-O-Vax 3.